Furthermore, Kim et al. [33] recently showed that the combination of the HDAC inhibitor entinostat and AZA, with anti-PD-1 and anti-CTLA4 achieved complete regression of tumors in mouse models of colorectal and breast cancer, and this was attributed to a significant decrease in the myeloid derived suppressor cells in the tumors. This evidence concerns the gene CTLA4 and breast carcinoma.